{"provider_url":"https://hatena.blog","title":"Repotrectinib in ROS1 Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer","author_url":"https://blog.hatena.ne.jp/towermansion/","published":"2024-02-27 03:28:17","categories":["lung cancer\uff5eNSCLC\uff5eStageIV\uff5eDriver+"],"blog_title":"\u52c9\u5f37\u7528","image_url":null,"blog_url":"https://towermansion.hatenablog.com/","provider_name":"Hatena Blog","type":"rich","description":"N Engl J Med. 2024 Jan 11;390(2):118-131. BACKGROUNDThe early-generation ROS1 tyrosine kinase inhibitors (TKIs) that are approved for thetreatment of ROS1 fusion\u2013positive non\u2013small-cell lung cancer (NSCLC) have antitumoractivity, but resistance develops in tumors, and intracranial activity is subopt\u2026","height":"190","width":"100%","html":"<iframe src=\"https://hatenablog-parts.com/embed?url=https%3A%2F%2Ftowermansion.hatenablog.com%2Fentry%2F2024%2F02%2F27%2F032817\" title=\"Repotrectinib in ROS1 Fusion\u2013Positive Non\u2013Small-Cell Lung Cancer - \u52c9\u5f37\u7528\" class=\"embed-card embed-blogcard\" scrolling=\"no\" frameborder=\"0\" style=\"display: block; width: 100%; height: 190px; max-width: 500px; margin: 10px 0px;\"></iframe>","url":"https://towermansion.hatenablog.com/entry/2024/02/27/032817","author_name":"towermansion","version":"1.0"}